eXoZymes (NASDAQ:EXOZ) Issues Earnings Results

eXoZymes (NASDAQ:EXOZ) released its earnings results on Thursday. The company reported ($0.33) earnings per share (EPS) for the quarter, Zacks reports.

eXoZymes Price Performance

eXoZymes stock traded up $0.20 during midday trading on Thursday, hitting $5.96. 4,541 shares of the stock were exchanged, compared to its average volume of 7,073. The company has a fifty day simple moving average of $6.60 and a two-hundred day simple moving average of $8.42. eXoZymes has a 52 week low of $4.35 and a 52 week high of $18.40. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.03.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of eXoZymes in a report on Friday, May 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

eXoZymes Company Profile

eXoZymes, Inc develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company’s enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows.

Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards.

eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide.